Prothena Corporation (PRTA) Stock Price
Prothena Corporation Price
Revenue has compounded at 8.8% per year over the past 16 years to 9.68 M USD. Prothena Corporation's net margin stands at -2,520.6%, down from 33.4% several years earlier. Analysts set a median price target of 24.50 USD, implying 192.5% above the current price. Of 12 analysts, 8 rate the stock a buy — an overall Buy consensus.
Prothena Corporation stock price
Prothena Corporation business model & stock analysis
Frequently asked questions about Prothena Corporation
The business model of Prothena Corporation PLC revolves around the development and commercialization of novel therapies for the treatment of progressive diseases. Prothena focuses on the discovery and development of protein immunotherapies, specifically targeting misfolded proteins that are implicated in various neurodegenerative diseases. Through its innovative approach, Prothena aims to address unmet medical needs and improve patient outcomes. By leveraging its expertise in protein engineering, it strives to create transformative therapies that have the potential to significantly impact the lives of patients. Prothena Corporation PLC is committed to advancing its pipeline and partnering with strategic collaborators to further accelerate the development and commercialization of its innovative therapies.
Prothena Corporation PLC is primarily active in the biotechnology and pharmaceutical industries.
Some of the main competitors of Prothena Corporation PLC in the market include Biogen Inc., Ionis Pharmaceuticals Inc., and Alexion Pharmaceuticals Inc.
Prothena Corporation PLC is a biotechnology company specializing in the discovery and development of novel therapies for neurodegenerative diseases. Established in 2012, Prothena originated as a spin-off from Elan Corporation, focusing primarily on antibody-based therapies. The company's research and development efforts are centered around misfolded proteins implicated in diseases like amyloidosis, Parkinson's, and Alzheimer's. With a commitment to scientific innovation, Prothena utilizes its expertise in protein engineering to create transformative treatments. By leveraging its strong pipeline and collaborations, Prothena aims to provide hope to patients suffering from debilitating disorders and improve their quality of life.
Prothena Corporation PLC has achieved several significant milestones. The company successfully generated positive results in its Phase 1 clinical trials for PRX002/RG7935, a potential treatment for Parkinson's disease. Furthermore, Prothena entered into a worldwide collaboration with Roche to develop and commercialize PRX002/RG7935, receiving an upfront payment and potential milestone payments. Additionally, Prothena advanced its pipeline with the initiation of Phase 1 clinical trials for PRX004, a potential therapy for ATTR amyloidosis. These milestones demonstrate Prothena Corporation PLC's progress in developing innovative treatments and forging key collaborations in the field of neurodegenerative diseases.
Prothena Corporation PLC is primarily present in the United States and Europe. As a multinational biotechnology company, Prothena focuses on the discovery, development, and commercialization of immunotherapies for the treatment of neurodegenerative diseases. With its headquarters in Ireland, Prothena maintains a strong presence in major cities across the United States, including South San Francisco and Cambridge. Additionally, the company has operations in several European countries, such as Switzerland and the United Kingdom. Prothena's global reach enables it to collaborate with renowned academic institutions, healthcare providers, and research organizations to advance innovative therapies for patients worldwide.
Prothena Corporation PLC is a biotechnology company that focuses on developing transformative therapies for patients with neurodegenerative diseases. The company's values revolve around scientific innovation, integrity, collaboration, and patient-centricity. Prothena is committed to advancing the understanding of disease pathways and developing novel treatments that address unmet medical needs. With a mission to improve patient outcomes, Prothena prioritizes rigorous research, strategic partnerships, and efficient development processes. By combining cutting-edge science, a strong corporate philosophy, and a dedicated team, Prothena Corporation PLC strives to bring hope and potential breakthroughs to individuals affected by debilitating neurodegenerative conditions.
Analysts currently set an average price target of 24.50 USD for the Prothena Corporation stock (median: 24.50 USD), implying +186.9 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Prothena Corporation stock: 8 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Prothena Corporation to generate revenue of 83.16 M USD and earnings per share of 0.11 USD.
Converted at the current exchange rate, the Prothena Corporation share trades at 7.43 EUR (8.38 USD).
The Prothena Corporation share (PRTA) is listed on 5 stock exchanges, including: NASDAQ (PRTA), London (0Y3M.L), Frankfurt (0PT.F), München (0PT.MU), Düsseldorf (0PT.DU).
Prothena Corporation PLC is a leading biotechnology company specializing in the development of therapies for neurodegenerative diseases. The company, founded in 2012, is headquartered in Dublin, Ireland, and its main focus is on developing drugs against amyloid deposition in brain cells. The company's research and development division is the core of the company, where drugs targeting amyloid deposition in brain cells are developed. Prothena's production department guarantees that the drugs are produced in the highest quality and comply with strict regulatory requirements. Once a drug is approved by the FDA or EMA, Prothena markets and sells it. Prothena has developed NEOD001, a drug in clinical phase III, targeting patients with secondary systemic amyloidosis. The company also has other drugs in the pipeline focusing on Alzheimer's, Parkinson's, and ALS. Overall, Prothena is an innovative biotechnology company that makes a significant contribution to research on neurodegenerative diseases. Its focus on identifying specific antibodies against amyloid deposits in the brain is a promising approach with the potential to improve the lives of millions of people.
The expected revenue of Prothena Corporation is 83.16 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Prothena Corporation is 5.92 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Prothena Corporation is currently 76.14. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Prothena Corporation stock.
The price-to-sales ratio (P/S) of Prothena Corporation is currently 5.42. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Prothena Corporation stock.
The Eulerpool Quality Score for Prothena Corporation is 2/10.
The ISIN of Prothena Corporation is IE00B91XRN20. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Prothena Corporation is A1KAVV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Prothena Corporation is PRTA. The ticker symbol is used to trade Prothena Corporation shares on the stock exchange.
Prothena Corporation stock
Prothena Corporation Peer Group
Prothena Corporation Ticker
Prothena Corporation FIGI
All fundamentals and in-depth analysis of Prothena Corporation
Our stock analysis for Prothena Corporation stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Prothena Corporation. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.